Works matching IS 87551225 AND DT 2025 AND VI 41 AND IP 2
Results: 6
Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 83, doi. 10.1177/87551225241308475
- By:
- Publication type:
- Article
State Variation in Uptake of Pharmacy-Based CLIA-Waived Testing: Impact of Laws and Regulations.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 95, doi. 10.1177/87551225241306678
- By:
- Publication type:
- Article
Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 90, doi. 10.1177/87551225241306675
- By:
- Publication type:
- Article
Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Vs Non-Fluoroquinolone Antibiotics for Urinary Tract Infection (UTI).
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 72, doi. 10.1177/87551225241303848
- By:
- Publication type:
- Article
Effectiveness and Safety of Sodium-Glucose Cotransporter-2 Inhibitor Continuation in Patients With Type 2 Diabetes and Late-Stage Chronic Kidney Disease.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 65, doi. 10.1177/87551225241302731
- By:
- Publication type:
- Article
Optimizing Heparin Quality Assurance Utilizing Electronic Data Abstraction.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 59, doi. 10.1177/87551225241299691
- By:
- Publication type:
- Article